Barriers to progress - The impact of tolerability problems

International Clinical Psychopharmacology

Volumn 16, Issue SUPPL. 1, 2001, Pages

  Casey, D E ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Antipsychotics; Compliance; Side effects; Tolerability

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; DOPAMINE 2 RECEPTOR; HISTAMINE H1 RECEPTOR; MUSCARINIC M1 RECEPTOR; NEUROLEPTIC AGENT; SEROTONIN 2 RECEPTOR; ZIPRASIDONE;

CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; VERTIGO; WEIGHT GAIN;

EID: 0035110191     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200101001-00004     Document Type: Conference Paper

References (22)

1. Antipsychotic - Induced weight gain: A comprehensive research synthesis
2. Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia
3. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
4. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
5. A two-year prospective study of treatment compliance in patients with schizophrenia
6. The relationship of pharmacology to side-effects
7. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
8. Compliance with antipsychotic drug treatment: Influence of side-effects
9. Psychotropic medications and their effect on sexual function: Diagnosis, biology and treatment approaches
10. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder
11. Preclinical profile of Seroquel (quetiapine): An atypical antipsychotic with clozapine-like pharmacology
12. Management strategies for the treatment of schizophrenia
13. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
14. Receptor interactions of new antipsychotics: Relation to pharmacodynamic and clinical effects
15. Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypotheses of schizophrenia
16. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder
17. Prevalence of obesity in patients receving depot antipsychotics
18. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
19. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
20. Why do schizophrenic patients refuse to take their drugs?
21. Medication noncompliance in schizophrenia: Codification and update
22. Pharmacological and neurochemical studies with the new antipsychotic ziprasidone